Research ArticleArticle
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study
Jean W. Liew, John D. Reveille, Maria Castillo, Henna Sawhney, Benjamin S. Naovarat, Susan R. Heckbert and Lianne S. Gensler
The Journal of Rheumatology July 2020, jrheum.200188; DOI: https://doi.org/10.3899/jrheum.200188
Jean W. Liew
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
John D. Reveille
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
Maria Castillo
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
Henna Sawhney
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
Benjamin S. Naovarat
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
Susan R. Heckbert
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
Lianne S. Gensler
JL received a National Institutes of Health T32 training grant (T32AR007108) and funding from the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). LG received support from the Spondylitis Association of America and the Russel Engelman Rheumatology Research Center at the University of California, San Francisco. 1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; 2J.D. Reveille, MS, B.S. Naovarat, MD, Division of Rheumatology and Clinical Immunogenetics, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas; 3M. Castillo, MS, H. Sawhney, MD, University of California San Francisco, San Francisco, California; 4S.R. Heckbert, MD, PhD, Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington; 5L.S. Gensler, MD, Department of Medicine/Rheumatology, Russell Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA. JR receives consulting fees from Eli Lilly, Janssen, Novartis, Pfizer, and UCB. LG receives consulting fees from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, and UCB (under $10,000); and grant/research support from UCB, Novartis, and Pfizer. The other authors declare no conflicts of interest. Address correspondence to Dr. J.W. Liew, University of Washington, 1959 NE Pacific St, BB561, Seattle, WA 98195, USA. Email: jwliew@uw.edu. Accepted for publication June 22, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study
Jean W. Liew, John D. Reveille, Maria Castillo, Henna Sawhney, Benjamin S. Naovarat, Susan R. Heckbert, Lianne S. Gensler
The Journal of Rheumatology Jul 2020, jrheum.200188; DOI: 10.3899/jrheum.200188
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study
Jean W. Liew, John D. Reveille, Maria Castillo, Henna Sawhney, Benjamin S. Naovarat, Susan R. Heckbert, Lianne S. Gensler
The Journal of Rheumatology Jul 2020, jrheum.200188; DOI: 10.3899/jrheum.200188